VIP and Hyperglycemia: Maugeri et al. [6] have demonstrated that the pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) could inhibit the hyperglycemia/hypoxia-induced retinal dysfunction in patients with DR.